Browse more cannabis research, findings, methods, and limitations.
Lab tests showed THC/THCA-dominant cannabis extracts protected brain cells from Alzheimer's-related amyloid-beta toxicity, but not by preventing plaque formation.
College drinkers with ADHD had worse sleep and more alcohol-related consequences, but ADHD did not increase cannabis-related negative outcomes.
CHS hospitalizations increased fivefold after Massachusetts cannabis legalization, with hospital stays tripling and costs more than doubling per admission.
Boosting the endocannabinoid 2-AG in mice blocked opioid reward without reducing pain relief, suggesting a potential strategy to make opioid treatment less addictive.
A mouse study showed CB1 receptor activation protected against glutamate-induced brain damage by reducing oxidative stress through the NOX-2 pathway.
A mouse study found endocannabinoid levels rise in the cervix during pregnancy, and inflammation-induced disruption promotes premature cervical remodeling.
A review found CBD shows anti-cancer properties through multiple molecular pathways that trigger cancer cell death.
A 7-year-old experienced cardiac arrest 7 hours after eating THC gummies, the first pediatric case of THC-induced asystole.
A longitudinal study of 7,464 Australian men found cannabis use linked to transitioning from suicidal thoughts to attempts, while alcohol was not.
While CBD works for several genetic epilepsies, evidence for CDKL5 Deficiency Disorder remains largely anecdotal.
Cannabis health warnings triggered fear and hope, both driving protective intentions, though pictures added no benefit over text.
A systematic review found CBT shows promise for adolescent CUD, with shorter courses and parental involvement most promising.
Medical cannabis laws with dispensaries were associated with declining CUD treatment in 2004-2014, though the effect faded by 2015-2019.
Cannabinoids protected brain mitochondria from toxic damage by activating mitochondrial CB1 receptors.
CBD-dominant cannabis extract improved communication, attention, and behavior while reducing aggression in 30 children with moderate-severe autism.
A placebo-controlled trial found 150mg CBD had no effect on mood, enjoyment, pain, or performance during a 10km run.
Most tobacco-cannabis co-users tried tobacco first, with nicotine e-cigarettes the most common initial product, especially among teens.
Analysis of 920 participants found reducing cannabis use ~50% in frequency and ~75% in amount was associated with clinician-assessed improvement.
A study of 11,363 Ontario youth found cannabis use was associated with 11-fold psychosis risk during adolescence but no significant risk during young adulthood.
A clinical review highlights that CHS is under-diagnosed, resists standard anti-nausea drugs, and requires abstinence for long-term resolution.
Australian nurses want to discuss medicinal cannabis with patients but feel underprepared, highlighting education gaps.
Content analysis finds most US states with legal cannabis have weak warning labels averaging 57 words, with almost none requiring mental health or psychosis risk warnings.
Randomized trial found that A-CRA therapy helped Iranian teen boys with cannabis use disorder achieve higher abstinence and better family relationships than standard treatment.
First identification of cannabinoid receptor complexes (CB1-GPR55 and CB2-GPR55) in human brain tissue, with significant upregulation in multiple sclerosis patients.
Legalization strengthened the link between seeing cannabis as low-risk and using it, but broke the link between use and seeking treatment, leading to declining teen treatment admissions.
Pregnant people using cannabis for nausea reported stigmatizing reactions from healthcare providers, leading many to conceal their use, while medication users received only positive feedback.
Two adolescent CHS cases and a literature review reveal dangerous QTc prolongation risks when haloperidol treatment compounds the cardiac effects of cannabis and electrolyte imbalances from vomiting.
Large national survey finds cannabis users are 24% more likely to be physically active, with the strongest association in states with legal recreational cannabis.
A single educational session on medical marijuana significantly improved knowledge across all provider types, while chart review revealed 83% of marijuana-using patients had potential drug interactions.
Four weeks of cannabis abstinence restored default mode network activity and improved cognition across multiple domains in people with MS who were frequent users.
Narrative review finds strongest evidence for THC-based medical cannabis in chronic neuropathic pain and balanced THC/CBD products for MS spasticity, with manageable side effects and low dependence risk.
In nearly 10,000 children, brain structural differences including thinner prefrontal cortex and larger overall brain volume preceded and predicted substance use initiation before age 15.
Cannabis users showed reduced demand when imagining driving but increased demand in sleep contexts with cannabis cues, suggesting safety concerns can override drug motivation.
After controlled THC dosing, cannabis users who felt unsafe to drive showed more impairment — but some who felt safe were still impaired, especially experienced users.
JAMA review finds cannabis use affects every surgical care phase from anesthesia dosing to wound healing and drug interactions, yet most patients do not disclose use to surgeons.
Evening chronotype and cannabis use disorder independently predicted earlier bipolar mood symptom onset, suggesting circadian rhythm disruption may underlie both conditions.
Mississippi YRBS data shows cannabis use among high schoolers clusters with vaping, tobacco, alcohol, and sexual behaviors, with no gender or racial differences in cannabis use rates.
Review finds natural cannabinoids may protect kidneys through CB2 activation and help prevent stones, while synthetic cannabinoids pose serious acute kidney injury risk.
CB2 receptors on brain microglia drove neuroinflammation in graft-versus-host disease, and a brain-penetrant CB2 blocker selectively reduced it without worsening the systemic immune response.
Primate pilot study found prenatal THC exposure had narrow effects on fetal muscle development overall, but activated inflammation and cytokine pathways suggesting potential for longer-term tissue damage.
Study of 50 people who abused both amphetamines and cannabis found significant white blood cell changes and 70% positive for fungal lung infections.
Review finds CBD shows strong preclinical promise for gut and lung diseases, but its poor absorption and metabolism create a major gap between lab results and real-world clinical outcomes.
Evidence map of 194 studies found medical cannabis showed positive effects in 57% of treatment descriptions across 71 health outcomes, with strongest support for pain, seizures, and spasticity.
Opioid-naive cannabis users needed nearly twice the morphine equivalent doses after spinal fusion surgery compared to non-users, despite having fewer overall health problems.
Review of 59 studies finds prenatal cannabis exposure consistently predicts low birth weight followed by rapid weight gain, increased body fat, and higher glucose in childhood.
In a rat schizophrenia vulnerability model, adolescent THC impaired social behavior but did not worsen or interact with prenatal immune activation-induced cognitive deficits.
Adults prenatally exposed to cocaine started cannabis younger, and this earlier onset mediated the path to higher anxiety and more severe cannabis use in adulthood.
National Canadian survey finds 15.6% of adults use cannabis for sleep, surpassing prescription medication use, with young men most likely to choose cannabis.
A non-euphoric cannabis extract reduced inflammatory pain in rats without the behavioral impairment caused by THC or synthetic cannabinoids, supporting the entourage effect.
Among 360 Swiss cannabis users, depression and ADHD specifically predicted heavier use after controlling for other factors, while anxiety and psychosis associations disappeared.